These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 15101715)

  • 1. Serum levels of CD137 ligand and CD178 are prognostic factors for progression of myelodysplastic syndrome.
    Salih HR; Nuessler V; Denzlinger C; Starling GC; Kiener PA; Schmetzer HM
    Leuk Lymphoma; 2004 Feb; 45(2):301-8. PubMed ID: 15101715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serum levels of sCD137 (4-1BB) ligand are prognostic factors for progression in acute myeloid leukemia but not in non-Hodgkin's lymphoma.
    Hentschel N; Krusch M; Kiener PA; Kolb HJ; Salih HR; Schmetzer HM
    Eur J Haematol; 2006 Aug; 77(2):91-101. PubMed ID: 16800841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fas/Fas-ligand expressions in peripheral-blood mononuclear cells of patients with myelodysplastic syndromes.
    Hirano T; Hiratsuka N; Iwahori T; Oka K; Wakasugi K
    Res Commun Mol Pathol Pharmacol; 2003; 113-114():315-28. PubMed ID: 15686130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fas ligand expression in the bone marrow in myelodysplastic syndromes correlates with FAB subtype and anemia, and predicts survival.
    Gupta P; Niehans GA; LeRoy SC; Gupta K; Morrison VA; Schultz C; Knapp DJ; Kratzke RA
    Leukemia; 1999 Jan; 13(1):44-53. PubMed ID: 10049059
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
    Bouscary D; De Vos J; Guesnu M; Jondeau K; Viguier F; Melle J; Picard F; Dreyfus F; Fontenay-Roupie M
    Leukemia; 1997 Jun; 11(6):839-45. PubMed ID: 9177438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of TNF receptors and related signaling molecules in the bone marrow from patients with myelodysplastic syndromes.
    Sawanobori M; Yamaguchi S; Hasegawa M; Inoue M; Suzuki K; Kamiyama R; Hirokawa K; Kitagawa M
    Leuk Res; 2003 Jul; 27(7):583-91. PubMed ID: 12681357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of CD137 and CD137 ligand in colorectal cancer patients.
    Dimberg J; Hugander A; Wågsäter D
    Oncol Rep; 2006 May; 15(5):1197-200. PubMed ID: 16596186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A role for tumour necrosis factor-alpha, Fas and Fas-Ligand in marrow failure associated with myelodysplastic syndrome.
    Gersuk GM; Beckham C; Loken MR; Kiener P; Anderson JE; Farrand A; Troutt AB; Ledbetter JA; Deeg HJ
    Br J Haematol; 1998 Oct; 103(1):176-88. PubMed ID: 9792306
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Expression of Fas, FasL and Bcl-2 and apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome].
    Zhang Z; Xie J
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):274-7. PubMed ID: 12844412
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A study on early activation of T lymphocytes and soluble tumor necrosis factor receptor in patients with myelodysplastic syndrome].
    Shen R; Xu CG; Li LZ; Zhang T; Qin XM; Li J
    Zhonghua Nei Ke Za Zhi; 2003 Dec; 42(12):857-60. PubMed ID: 14728878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome.
    Deeg HJ; Beckham C; Loken MR; Bryant E; Lesnikova M; Shulman HM; Gooley T
    Leuk Lymphoma; 2000 Apr; 37(3-4):405-14. PubMed ID: 10752992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endogenous FLT-3 ligand serum levels are associated with disease stage in patients with myelodysplastic syndromes.
    Zwierzina H; Anderson JE; Rollinger-Holzinger I; Torok-Storb B; Nuessler V; Lyman SD
    Leukemia; 1999 Apr; 13(4):553-7. PubMed ID: 10214861
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid induction of CD95 ligand and CD4+ T cell-mediated apoptosis by CD137 (4-1BB) costimulation.
    Ebata T; Mogi S; Hata Y; Fujimoto JI; Yagita H; Okumura K; Azuma M
    Eur J Immunol; 2001 May; 31(5):1410-6. PubMed ID: 11465097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The level of bone marrow WT1 message is a useful marker to differentiate myelodysplastic syndromes with low blast percentage from cytopenia due to other reasons.
    Baba M; Hata T; Tsushima H; Mori S; Sasaki D; Turuta K; Hasegawa H; Ando K; Sawayama Y; Imanishi D; Taguchi J; Yanagihara K; Tomonaga M; Kamihira S; Miyazaki Y
    Intern Med; 2015; 54(5):445-51. PubMed ID: 25758068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.
    Loeffler-Ragg J; Germing U; Sperr WR; Herrmann H; Zwierzina H; Valent P; Ulmer H; Stauder R
    Crit Rev Oncol Hematol; 2011 May; 78(2):150-61. PubMed ID: 20580567
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum evaluation of angiogenic cytokine basic fibroblast growth factor, hepatocyte growth factor and TNF-alpha in patients with myelodysplastic syndromes: correlation with bone marrow microvascular density.
    Alexandrakis MG; Passam FH; Pappa CA; Damilakis J; Tsirakis G; Kandidaki E; Passam AM; Stathopoulos EN; Kyriakou DS
    Int J Immunopathol Pharmacol; 2005; 18(2):287-95. PubMed ID: 15888251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Fas and Fas ligand: Expression and soluble circulating levels in bile duct carcinoma.
    Murakami M; Sasaki T; Miyata H; Yamasaki S; Kuwahara K; Chayama K
    Oncol Rep; 2004 Jun; 11(6):1183-6. PubMed ID: 15138553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD137 and CD137 ligand constitutively coexpressed on human T and B leukemia cells signal proliferation and survival.
    Palma C; Binaschi M; Bigioni M; Maggi CA; Goso C
    Int J Cancer; 2004 Jan; 108(3):390-8. PubMed ID: 14648705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical prognostic factors for survival and risk of progression to acute myeloid leukemia in patients with myelodysplastic syndromes with < 10% marrow blasts and non-unfavorable cytogenetic categories.
    Falantes JF; Calderón C; Márquez Malaver FJ; Alonso D; Martín Noya A; Carrillo E; Martino ML; Montero I; González J; Parody R; Espigado I; Pérez-Simón JA
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):144-52. PubMed ID: 23137720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Abnormalities of CD34+ cells differentiation and bone marrow cell cycle in myelodysplastic syndrome].
    Li LJ; Fu R; Shao ZH; Wang HQ; Yue LZ; Ruan EB; Liu H; Wang J; Wang HL
    Zhonghua Nei Ke Za Zhi; 2010 Nov; 49(11):963-6. PubMed ID: 21211213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.